Patterns of antiseizure medication utilization in the Human Epilepsy Project.
natural history
polytherapy
sequential monotherapy
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
13
10
2023
received:
28
07
2023
accepted:
13
10
2023
pubmed:
17
10
2023
medline:
17
10
2023
entrez:
17
10
2023
Statut:
ppublish
Résumé
This study was undertaken to ascertain the natural history and patterns of antiseizure medication (ASM) use in newly diagnosed focal epilepsy patients who were initially started on monotherapy. The data were derived from the Human Epilepsy Project. Differences between the durations of the most commonly first prescribed ASM monotherapies were assessed using a Cox proportional hazards model. Subjects were classified into three groups: monotherapy, sequential monotherapy, and polytherapy. A total of 443 patients were included in the analysis, with a median age of 32 years (interquartile range [IQR] = 20-44) and median follow-up time of 3.2 years (IQR = 2.4-4.2); 161 (36.3%) patients remained on monotherapy with their initially prescribed ASM at the time of their last follow-up. The mean (SEM) and median (IQR) duration that patients stayed on monotherapy with their initial ASM was 2.1 (2.0-2.2) and 1.9 (.3-3.5) years, respectively. The most commonly prescribed initial ASM was levetiracetam (254, 57.3%), followed by lamotrigine (77, 17.4%), oxcarbazepine (38, 8.6%), and carbamazepine (24, 5.4%). Among those who did not remain on the initial monotherapy, 167 (59.2%) transitioned to another ASM as monotherapy (sequential monotherapy) and 115 (40.8%) ended up on polytherapy. Patients remained significantly longer on lamotrigine (mean = 2.8 years, median = 3.1 years) compared to levetiracetam (mean = 2.0 years, median = 1.5 years) as a first prescribed medication (hazard ratio = 1.5, 95% confidence interval = 1.0-2.2). As the study progressed, the proportion of patients on lamotrigine, carbamazepine, and oxcarbazepine as well as other sodium channel agents increased from a little more than one third (154, 34.8%) of patients to more than two thirds (303, 68.4%) of patients. Slightly more than one third of focal epilepsy patients remain on monotherapy with their first prescribed ASM. Approximately three in five patients transition to monotherapy with another ASM, whereas approximately two in five end up on polytherapy. Patients remain on lamotrigine for a longer duration compared to levetiracetam when it is prescribed as the initial monotherapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3196-3204Informations de copyright
© 2023 International League Against Epilepsy.
Références
Thijs RD, Surges R, O'Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393:689-701.
Brodie M, Barry S, Bamagous G, Norrie J, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548-1554.
Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279-286.
Pisani LR, Nikanorova M, Landmark CJ, Johannessen SI, Pisani F. Specific patient features affect antiepileptic drug therapy decisions: focus on gender, age, and psychiatric comorbidities. Curr Pharm Des. 2017;23:5639-5648.
Beniczky S, Rampp S, Asadi-Pooya AA, Rubboli G, Perucca E, Sperling MR. Optimal choice of antiseizure medication: agreement among experts and validation of a web-based decision support application. Epilepsia. 2021;62:220-227.
Bjørk M-H, Zoega H, Leinonen MK, Cohen JM, Dreier JW, Furu K, et al. Association of Prenatal Exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurol. 2022;79:672-681.
Faught E, Helmers S, Thurman D, Kim H, Kalilani L. Patient characteristics and treatment patterns in patients with newly diagnosed epilepsy: a US database analysis. Epilepsy Behav. 2018;85:37-44.
Patocka J, Wu Q, Nepovimova E, Kuca K. Phenytoin - an anti-seizure drug: overview of its chemistry, pharmacology and toxicology. Food Chem Toxicol. 2020;142:111393.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397:1363-1374.
Jain SV, Glauser TA. Effects of epilepsy treatments on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics. Epilepsia. 2014;55:26-37.
Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav. 2007;10:148-154.
Labiner DM, Ettinger AB, Fakhoury TA, Chung SS, Shneker B, Tatum WO IV, et al. Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia. 2009;50:434-442.
Knight R, Wittkowski A, Bromley RL. Neurodevelopmental outcomes in children exposed to newer antiseizure medications: a systematic review. Epilepsia. 2021;62:1765-1779.
Hernández-Díaz S, Smith C, Shen A, Mittendorf R, Hauser W, Yerby M, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78:1692-1699.
Vajda FJ, O'Brien TJ, Lander CM, Graham J, Eadie MJ. Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia. 2016;57:1048-1052.
Janmohamed M, Lawn N, Spilsbury K, Chan J, Dunne J. Starting a new anti-seizure medication in drug-resistant epilepsy: add-on or substitute? Epilepsia. 2021;62:228-237.
Martínez-Lizana E, Gil-Lopez F, Donaire A, Aparicio J, Brandt A, Carreño M. Outcome of treatment changes in patients with drug-resistant chronic epilepsy: a tertiary center experience. Epilepsy Res. 2017;136:97-102.